Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager. The report covers the calendar quarter ended March 31, 2024. The filing was signed by Amit Singh, Senior Vice President and Head of Treasury, on February 13, 2025.
Key Financial Metrics
As a Form 13F filing, this document reports equity holdings rather than the company's operational financial performance. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity for Takeda Pharmaceutical Co Ltd is not present in this text.
- Total Value of Reported Holdings: $289,040,735
- Number of Holdings Reported: 17
- Other Included Managers: 1 (Takeda Vaccines, Inc.)
Material Changes
The filing text does not provide comparative data against the prior period (December 31, 2023) to determine material changes in holdings or value. The document serves as a snapshot of holdings at the end of the reporting period.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, future guidance, risk factors, or contingencies related to the company's business operations. It strictly discloses the manager's reportable equity positions.
Investor Verification Checklist
- Verify the total value of $289,040,735 represents the aggregate value of the 17 reported equity positions.
- Confirm the inclusion of "Takeda Vaccines, Inc." as an other included manager under file number 028-24939.
- Note that this document does not reflect Takeda Pharmaceutical Co Ltd's own financial health, only its investment portfolio.